title: Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
abstract: The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. The first patient was alive at 8 years with alternative conventional chemotherapy and gefitinib, and the second patient was alive at long-term follow-up with conventional chemotherapy and gefitinib or erlotinib. Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC.
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: M X
authors.initials: MX
authors.lastname: Zhang
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: W
authors.initials: W
authors.lastname: Tan
authors.affiliation: Nursing Department of Shandong Medical College, Jinan, Shandong, China.
authors.forename: R X
authors.initials: RX
authors.lastname: Zhang
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Y L
authors.initials: YL
authors.lastname: Tian
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: H M
authors.initials: HM
authors.lastname: Gao
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Gao
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: N
authors.initials: N
authors.lastname: Zhang
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: J Q
authors.initials: JQ
authors.lastname: Zhao
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China.
authors.forename: Y F
authors.initials: YF
authors.lastname: Jia
authors.affiliation: Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, China sdjnwys@163.com.
authors.forename: Y S
authors.initials: YS
authors.lastname: Wang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib